Literature DB >> 32020555

Sodium Oligomannate: First Approval.

Yahiya Y Syed1.   

Abstract

Sodium oligomannate (®; GV-971) is a marine algae-derived oral oligosaccharide being developed by Shanghai Green Valley Pharmaceuticals for the treatment of Alzheimer's disease (AD). Sodium oligomannate received its first approval in November 2019 in China for the treatment of mild to moderate AD to improve cognitive function. This article summarizes the milestones in the development of sodium oligomannate leading to this first approval for AD.

Entities:  

Year:  2020        PMID： 32020555     DOI： 10.1007/s40265-020-01268-1

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  27 in total

Review 1.  Biological Potential, Gastrointestinal Digestion, Absorption, and Bioavailability of Algae-Derived Compounds with Neuroprotective Activity: A Comprehensive Review.

Authors:  Bruna Martins; Mónica Vieira; Cristina Delerue-Matos; Clara Grosso; Cristina Soares
Journal:  Mar Drugs       Date:  2022-05-28       Impact factor: 6.085

Review 2.  Neurovascular Dysfunction in Diverse Communities With Health Disparities-Contributions to Dementia and Alzheimer's Disease.

Authors:  Napatsorn Saiyasit; Evan-Angelo R Butlig; Samantha D Chaney; Miranda K Traylor; Nanako A Hawley; Ryleigh B Randall; Hanna V Bobinger; Carl A Frizell; Franklin Trimm; Errol D Crook; Mike Lin; Benjamin D Hill; Joshua L Keller; Amy R Nelson
Journal:  Front Neurosci       Date:  2022-06-29       Impact factor: 5.152

Review 3.  Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version.

Authors:  Jiaxi Xie; Cailing Zhong; Tingting Wang; Dan He; Luyang Lu; Jie Yang; Ziyi Yuan; Jingqing Zhang
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

4.  Ginkgo Biloba Leaf Extract Improves an Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer's Disease Patients.

Authors:  Marta Sochocka; Michał Ochnik; Maciej Sobczyński; Katarzyna Gębura; Aleksandra Zambrowicz; Piotr Naporowski; Jerzy Leszek
Journal:  Nutrients       Date:  2022-05-11       Impact factor: 6.706

5.  Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update.

Authors:  Chao-Chao Yu; Yan-Jun Du; Jin Li; Yi Li; Li Wang; Li-Hong Kong; Ying-Wen Zhang
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

6.  Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer's disease.

Authors:  Ning Yan; Xiao-Long Shi; Long-Qian Tang; De-Feng Wang; Xun Li; Chao Liu; Zhao-Peng Liu
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

7.  Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in China.

Authors:  Jiaojiao Lu; Qiongqun Pan; Jieqiang Zhou; Yan Weng; Kaili Chen; Lv Shi; Guanxiu Zhu; Chunlin Chen; Liang Li; Meiyu Geng; Zhenqing Zhang
Journal:  J Pharm Anal       Date:  2021-06-05

Review 8.  New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.

Authors:  Feng Zhang; Ru-Jia Zhong; Cheng Cheng; Song Li; Wei-Dong Le
Journal:  Acta Pharmacol Sin       Date:  2020-12-02       Impact factor: 7.169

Review 9.  Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.

Authors:  Priscila Baltazar Gonçalves; Ana Carolina Rennó Sodero; Yraima Cordeiro
Journal:  Biomolecules       Date:  2021-05-20

10.  Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.

Authors:  Jeffrey Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-10-28       Impact factor: 2.198
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.